BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 15356792)

  • 21. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis.
    Pavie J; Lacroix C; Hermoso DG; Robin M; Ferry C; Bergeron A; Feuilhade M; Dromer F; Gluckman E; Molina JM; Ribaud P
    J Clin Microbiol; 2005 Sep; 43(9):4902-4. PubMed ID: 16145172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changing epidemiology of systemic fungal infections.
    Richardson M; Lass-Flörl C
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():5-24. PubMed ID: 18430126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy.
    Trifilio SM; Bennett CL; Yarnold PR; McKoy JM; Parada J; Mehta J; Chamilos G; Palella F; Kennedy L; Mullane K; Tallman MS; Evens A; Scheetz MH; Blum W; Kontoyiannis DP
    Bone Marrow Transplant; 2007 Apr; 39(7):425-9. PubMed ID: 17310132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Case report: Invasive aspergillosis successfully treated with voriconazole without recurrence during subsequent bone marrow transplantation.
    Chow E; Moore T; Nielsen K
    Pediatr Infect Dis J; 2003 Dec; 22(12):1109-10. PubMed ID: 14688580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole.
    Alexander BD; Schell WA; Miller JL; Long GD; Perfect JR
    Transplantation; 2005 Sep; 80(6):868-71. PubMed ID: 16210978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine.
    Krishnan-Natesan S; Chandrasekar PH; Manavathu EK; Revankar SG
    Diagn Microbiol Infect Dis; 2008 Dec; 62(4):443-6. PubMed ID: 18842377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Voriconazole in newborns.
    Kohli V; Taneja V; Sachdev P; Joshi R
    Indian Pediatr; 2008 Mar; 45(3):236-8. PubMed ID: 18367773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breakthrough fungemia due to Candida glabrata during posaconazole prophylaxis in hematology patients treated with anidulafungin - report of 5 cases.
    Krcmery V; Demitrovicova A; Kisac P
    J Chemother; 2011 Oct; 23(5):310-1. PubMed ID: 22005067
    [No Abstract]   [Full Text] [Related]  

  • 29. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
    Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
    Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
    Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
    Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
    Shorr AF; Lazarus DR; Sherner JH; Jackson WL; Morrel M; Fraser VJ; Kollef MH
    Crit Care Med; 2007 Apr; 35(4):1077-83. PubMed ID: 17312565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of voriconazole, granulocyte-macrophage colony-stimulating factor, and interferon gamma on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages.
    Baltch AL; Bopp LH; Smith RP; Ritz WJ; Carlyn CJ; Michelsen PB
    Diagn Microbiol Infect Dis; 2005 Aug; 52(4):299-304. PubMed ID: 15893901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breakthrough Candida infections in patients receiving voriconazole.
    Gerzenshtein L; Patel SM; Scarsi KK; Postelnick MJ; Flaherty JP
    Ann Pharmacother; 2005; 39(7-8):1342-5. PubMed ID: 15914520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.
    Madureira A; Bergeron A; Lacroix C; Robin M; Rocha V; de Latour RP; Ferry C; Devergie A; Lapalu J; Gluckmana E; Socié G; Ghannoum M; Ribaud P
    Int J Antimicrob Agents; 2007 Dec; 30(6):551-4. PubMed ID: 18029149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing.
    Buchta V; Vejsova M; Vale-Silva LA
    Folia Microbiol (Praha); 2008; 53(2):153-60. PubMed ID: 18837162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis.
    Kobayashi K; Kami M; Murashige N; Kishi Y; Fujisaki G; Mitamura T
    Haematologica; 2004 Nov; 89(11):ECR42. PubMed ID: 15533847
    [No Abstract]   [Full Text] [Related]  

  • 38. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
    Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
    Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.
    Kontoyiannis DP; Lionakis MS; Lewis RE; Chamilos G; Healy M; Perego C; Safdar A; Kantarjian H; Champlin R; Walsh TJ; Raad II
    J Infect Dis; 2005 Apr; 191(8):1350-60. PubMed ID: 15776383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
    Arredondo-García JL; Amábile-Cuevas CF;
    J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.